According to an FDA warning letter, the agency found problems with microbial contamination in an inspection of the CMO's New Jersey facility earlier this year, affecting DPT's Santyl Ointment ...

The analysis compares the efficacy and safety of its product EscharEx® against SANTYL®, the only FDA-cleared enzymatic debridement agent. Key findings include that EscharEx achieved complete ...

to collagenase SANTYL ointment, approved by the FDA for debriding chronic dermal ulcers. SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated ...